Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Biktarvy in Trans People Living With HIV
NCT04944654Phase 4Terminated
- Sponsor
- Chelsea and Westminster Hospital NHS Foundation Trust
- Start
- Jan 2023
- Primary completion
- May 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 4 trial of bictegravir + emtricitabine + tenofovir alafenamide in human immunodeficiency virus infection (HIV), sponsored by Chelsea and Westminster Hospital NHS Foundation Trust. Started Jan 2023; status: terminated.
02
Drugs
bictegravir + emtricitabine + tenofovir alafenamide
03
Conditions
human immunodeficiency virus infection (HIV)
Beyond the preview
Go deeper on NCT04944654.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04944654.